Leadership

Sim Farar

Advisor

Mr. Farar brings to Biosig over 30 years of experience in both public and private sectors. Most recently, Mr. Farar was nominated by President J. Biden to serve as one of four United States representatives for the 76^th Session General Assembly of the United Nations. This nomination follows his appointment as United States Representative to the 54^th General Assembly from 1999-2000.  Remarkably, this is only the second time in history for someone to be appointed twice.

In 2002, Los Angeles Mayor James Hahn appointed Mr. Farar to serve as a commissioner for the $12 billion Los Angeles Fire and Police Pension’s Trustee Fund. In 2001, he was appointed to the Woodrow Wilson Council, the private sector advisory board of the Woodrow Wilson International Center for Scholars in Washington, DC. In 1999, he was appointed by President Clinton and confirmed by the U.S. Senate to serve as the United States Representative to the 54th General Assembly at the United Nations in New York City. In 1994, Mr. Farar received a Presidential appointment to the Advisory Committee on the Arts of the John F. Kennedy Center for Performing Arts in Washington, DC.

In the private sector, Mr. Farar has served as CEO, Chairman of the Board, Director, and consultant to a number of companies, including JDF Investment CO. LLC, IFC Financial Services Corp, and has served as an adviser to several other private and public companies.

Lorraine Spurge

Advisor

As founder and CEO of Maple Stone Capital Advisors, Ms. Spurge began her 40-year financial career with Drexel Burnham Lambert and became one of the most successful women on Wall Street. She managed the capital markets group for Drexel Burnham Lambert in the 1980s. At Drexel, she helped raise more than $200 billion for middle market growth companies. For the next two decades, she was an entrepreneur and CEO of International Capital Access, Knowledge Exchange and Spurge Ink!

As a motivational speaker, Ms. Spurge has been a contributor to radio and TV stations including CNN, CNBC, and KCBS, and authored several books including Portraits of the American Dream, MCI: Failure is not an Option, and Money Clips. She currently serves on the boards of EEM, Involvy, Nupulse, and Working Nation, and is a mentor for Women in America. She is an emeritus board member of the Prostate Cancer Foundation and has served on the Board of the Geffen Playhouse as well as the Board of Advisors for George Washington University.

Edwin Wang

Advisor

Mr. Wang has over 20 years of impactful experience in private equity, venture capital, merchant banking, and family office investing. He is the founder of Accretive Capital Partners LLC (2007), a pioneering direct secondary and co-investment sponsor in middle market private equity that successfully harvested a substantial co-investment in $660M Evercore Capital Partners II LP and $1.5B in separate accounts. From 2002 to 2007 while at predecessor affiliate Asymmetry Capital LLC, he led the successful financial restructuring and liquidation of $1B in venture capital portfolios from Zero Stage Capital whose legacy spawned a forerunner to Moderna. These accomplishments were chronicled in two Harvard Business School case studies and other publications, including The Deal Magazine. Previously, during an eight-year investment banking career he led Greater China cross-border direct investment at Credit Suisse and spearheaded a technology investment JV with Taipei-based China Development Bank culminating in $250M Asia Corporate Partners Fund whose investments comprised Texas Instruments/Acer, United Microelectronics and Taiwan Semiconductor Manufacturing.

Mr. Wang holds a B.A. in Economics from Columbia University and a Visiting Fellowship in Finance at the MIT Sloan School of Management under the tutelage of the late Nobel laureate, Dr. Franco Modigliani.

Dr. Ramachandra Malya, M.D.

Advisor

Dr. Malya brings to BioSig over 40 years of experience in the medical field. His strong business acumen has allowed Dr. Malya to serve as Founding Board Member of several successful healthcare entities and two Texas savings banks with valuations in excess of one billion dollars. Throughout his career, Dr. Malya raised capital for a number of promising healthcare start-ups and managed an important family office funds with extensive medical relationships. Dr. Malya is a Diplomate of American Board of Internal Medicine and American College of Managed Care Medicine.

Frank J. Quintero

Advisor

Mr. Quintero is a Principal at The Yucaipa Companies, a premier investment firm founded by Ron Burkle in 1986. His responsibilities as a Principal of the firm encompass deal origination, negotiating transactions, investor relations and corporate communications. Working closely with The Yucaipa Companies' founder, Mr. Quintero actively participated in multiple phases of the investment process since joining the firm. The Yucaipa Companies has completed mergers and acquisitions valued at more than $35 billion.

Prior to joining The Yucaipa Companies, Mr. Quintero served as Special Assistant to California Governor Gray Davis. In this position he served as a liaison to labor officials and business groups; as well as local, state, and national elected officials. Mr. Quintero was also an advisor to Governor Davis on over 300 boards and commission appointments within the California state government. Under Governor Davis' leadership the Appointments Unit placed more women and people of color in appointed positions than any of California's previous governors.  

Active in numerous statewide and local political campaigns, in 1998 Mr. Quintero worked as State Field Director for the California Democratic Party Coordinated Campaign. As part of the three-person team managing a budget of several million dollars, Mr. Quintero directed over thirty offices throughout the state and oversaw print, radio, and direct mail advertising. His efforts on behalf of the Coordinated Campaign's “Get-Out-The-Vote” drive produced record voter registration and turnout in low-income communities.

Based on his experience unifying divergent groups, Mr. Quintero was chosen as one of 60 Americans to receive a Marshall Fellowship in 2001. He became part of a team of scholars and government officials brought together to advise European Union member nations, NGOs, and the head of NATO on economic integration and immigration policy.

Zachariah P. Zachariah, M.D.

Advisor

Previously, Dr. Zachariah served on the Florida Board of Governors of the State University system from 2003 to 2010 and from 2017 to May 2019. He has been practicing interventional cardiology at Holy Cross Hospital since 1976 and as its Director of Cardiovascular Services until 2010. He has also served on the National Heart, Lung and Blood Institute at the National Institutes of Health from 1990 to 1993 and as a member of the U.S. delegation to the World Health Organization in Geneva, Switzerland. He also served as Chairman of the Florida Board of Medicine from 1990-1992, 2000-2001 and 2013-2014. He also served as a member of the President’s Advisory Commission on Asian Americans and Pacific Islanders appointed by President George W. Bush in 2001.

Dr. Zachariah is board-certified in internal medicine and cardiology and specializes in cardiology, cardiac catheterization, and interventional cardiology and has performed more than 30,000 heart catheterizations and interventional procedures in Broward County. He co-authored several scientific papers, and participated in various clinical trials.

He received his medical degree from the Armed Forces Medical College in India, and then completed his residency at St. Joseph’s Hospital and Medical Center in Paterson, New Jersey. He also completed a fellowship in interventional cardiology at the Cleveland Clinic Educational Foundation in Cleveland, Ohio.

Dr. Zachariah is a holder of numerous awards, including the Ellis Island American Legend Award, the Golden Heart Award from the American Heart Association, Freedom Foundation Medal of Honor from the Freedom Foundation at Valley Forge, and Ellis Island Medal of Honor.

Anthony Amato

CEO

Mr. Anthony Amato is a business leader and entrepreneurial thinker with an intuitive ability to rapidly assess challenges and identify growth opportunities. He quickly sees organizational vision and understands goals, taking appropriate ownership and action required to guide the team, achieving aggressive targets and performance levels. Anthony has hands-on executive skills at engaging and influencing key stakeholders to not only grow business but also to optimize profits.

Anthony founded InQuest Science in March 2017 and then acquired Bridge Associates International Pharmaceutical Consulting in March 2020. He is the former director of Sales for Mesa Labs (MLAB) in Denver CO, a Nasdaq listed corporation that specializes in providing quality control products and services to ensure the safety and efficacy of equipment used in hospitals, pharmaceutical, medical device manufacturers, blood banks, laboratories, pharmacies, and industrial facilities.

In July of 1999 he founded Amega Scientific Corporation. He grew the company from a startup operation to a worldwide industry leader. Anthony developed and managed a staff with multiple North American offices, establishing R&D, production, logistics, administration, and sales. Clients included pharmaceutical, biotech, hospitals, government facilities, and research universities. Amega Scientific was a leading innovator for the Environmental Monitoring System industry. Amega Scientific was an ISO 17025 corporation instituting GXP requirements. Amega Scientific was acquired by Mesa Labs in November 2013.

Mr. Amato graduated from Glassboro State College (New Jersey) in 1989, with a dual degree in business management and finance. Mr. Amato’s outstanding interpersonal, business development, team building, and management skills make him an asset to the Company’s board of directors.

Anthony Amato

CEO

Mr. Anthony Amato is a business leader and entrepreneurial thinker with an intuitive ability to rapidly assess challenges and identify growth opportunities. He quickly sees organizational vision and understands goals, taking appropriate ownership and action required to guide the team, achieving aggressive targets and performance levels. Anthony has hands-on executive skills at engaging and influencing key stakeholders to not only grow business but also to optimize profits.

Anthony founded InQuest Science in March 2017 and then acquired Bridge Associates International Pharmaceutical Consulting in March 2020. He is the former director of Sales for Mesa Labs (MLAB) in Denver CO, a Nasdaq listed corporation that specializes in providing quality control products and services to ensure the safety and efficacy of equipment used in hospitals, pharmaceutical, medical device manufacturers, blood banks, laboratories, pharmacies, and industrial facilities.

In July of 1999 he founded Amega Scientific Corporation. He grew the company from a startup operation to a worldwide industry leader. Anthony developed and managed a staff with multiple North American offices, establishing R&D, production, logistics, administration, and sales. Clients included pharmaceutical, biotech, hospitals, government facilities, and research universities. Amega Scientific was a leading innovator for the Environmental Monitoring System industry. Amega Scientific was an ISO 17025 corporation instituting GXP requirements. Amega Scientific was acquired by Mesa Labs in November 2013.

Mr. Amato graduated from Glassboro State College (New Jersey) in 1989, with a dual degree in business management and finance. Mr. Amato’s outstanding interpersonal, business development, team building, and management skills make him an asset to the Company’s board of directors.

Chris Baer

Director

Mr. Chris Baer brings more than 25 years of commercial experience in the medical device space across both large publicly held and smaller privately held organizations. He currently serves as the Chief Commercial Officer at CDL Nuclear Technologies. He started in this role in April 2022 and prior to that from June 2019 to April 2022 he served as the vice president of commercial operations at Impulse Dynamics. He also held several commercial leadership roles in the cardiac rhythm management and electrophysiology space including Vice President and general manager at St. Jude Medical / Abbott. Mr. Baer holds a pharmacy degree from The University of Pittsburgh. Mr. Baer’s extensive experience in the electrophysiology medical device space makes him a valuable member of our Board.

Frederick D. Hrkac

Director

Mr. Frederick D. Hrkac has more than 30 years of experience in the medical device industry as an Executive and Corporate Board Director. He currently serves on the Board of Serres in Helsinki, Finland since September 2018, and Spineart in Geneva, Switzerland as chairman of the Board since August 2017. In 2017, he served as senior vice president corporate development and from 2014-2016 served a senior vice president of global commercial operations of Biosensors International. From 2009-2011, Mr. Hrkac served as Europe, Middle East & Africa president of Boston Scientific where he was responsible for close to $2 billion of sales. From 2005-2009, Mr. Hrkac was an executive of Sorin Group CRM, Paris, France. And, from November 1990-April 2005 he lived in 6 different countries working as an executive for Johnson & Johnson including Biosense Webster, a Johnson & Johnson company having laid the groundwork strategically for the most successful J&J division of the last 20 years with sales growing from a few hundred million dollars to several billion dollars.  Mr. Hrkac holds an Honors Bachelor of Business Administration from the Wilfrid Laurier University, Waterloo, Ontario Canada. Mr. Hrkac brings extensive expertise in global marketing and strategic business development, making him a valuable resource for our Board.

Steven E. Abelman

Director

Mr. Steven E. Abelman has more than 30 years of commercial litigation experience and currently serves as a shareholder for Brownstein Hyatt Farber Schreck in Denver, CO.  Mr. Abelman is a trusted advisor and trial counsel to banks, lending institutions and a variety of organizations and recognized by his peers for his expertise at the intersection of litigation and transactional law.  Yearly recognized as a top bankruptcy attorney, Mr. Abelman has been a frequent lecturer on bankruptcy and creditors’ rights topics, and combines sage advice, objective counsel with effective advocacy. The combination of over 30 years of handling loan workouts and dissolutions provide him with unique transactional aptitude for a commercial litigator. He serves as a trusted advisor and trial counsel to many banks and other lending institutions, as well as to businesses of various sizes.

Mr. Abelman is especially known for his success in representing creditors in large commercial bankruptcy cases, receiverships, and foreclosures, defending banks in lender liability cases, and representing both debtors and creditors in workout scenarios and distressed asset sales. He also represents parties regarding UCC matters and equipment lessors. Mr. Abelman graduated with a J.D. in 1984 from Whittier College Law School and a B.S. in 1979 from University of Chicago; was admitted to the U.S. Supreme Court, U.S. District Court, District of Colorado in 1984. Mr. Abelman’s extensive legal experience makes him an asset to the Board.

Donald F. Browne, C.P.A.

Director

Mr. Donald F. Browne, C.P.A. is a graduate of La Salle College, 1972, with a B.S. in accounting and later became licensed as a certified public accountant from the state of New Jersey in 1980.  Mr. Browne’s career has included being employed as a divisional controller of Caddy Corporation of America and a controller for Full Line Foods, Inc.

In 1990, Mr. Browne’s career then transitioned to public accounting, a field in which he launched his own firm (which he continues to run and operate). Mr. Browne specializes in business accounting, including financial and tax reporting for businesses of several different industries and professions, concentrations in federal and state tax audits. Mr. Browne’s tax and financial expertise makes him a valuable asset to our Board of Directors.